A pilot study on effectiveness of oral mucositis pain control in hematopoietic stem cell transplant patients

Shu Ping Wong, Farida Hanim Islahudin

Research output: Contribution to journalArticle

Abstract

Effectiveness of oral mucositis (OM) pain control with the current standard of care management was assessed using clinician and self-reported scales in hematopoietic stem cell transplant (HSCT) patients. A prospective observational study was performed using clinician-assessed [World Health Organization (WHO)] Oral Toxicity Scales and selfreported scales [Oral Mucositis Daily Questionnaires (OMDQ)]. A total of 23 HSCT patients were included in the study. There were 100 recorded days of OM using WHO scores, and 144 recorded days of OM using OMDQ. A total of 14/23 (60.9%) patients experienced mucositis. The presence of OM was significantly associated with increase in actual body weight [t (21) = 2.15, p = 0.044], body surface area (BSA) [t (21) = 2.31, p = 0.031] and body mass index (BMI) [t(21) = 2.13, p = 0.044], longer hospital stays [t (21) = 2.45, p = 0.023], and busulphan-based regimens (χ = 4.32, p = 0.038). The degree of pain relief was significantly inversely correlated to both the degree of WHO graded OM severity (ρ = -0.586; p < 0.001) and the severity of self-reported pain (ρ = -0.375; p < 0.001). Both WHO and OMDQ significantly positively correlated in the clinical setting (p < 0.001). In conclusion, this study highlights the potential advantages of using patient self-reported scales in the local clinical setting. The use of the OMDQ self-reported scales could lead to earlier changes in therapy and may prove useful in HSCT patients.

Original languageEnglish
Pages (from-to)27-32
Number of pages6
JournalJournal of Applied Pharmaceutical Science
Volume9
Issue number3
DOIs
Publication statusPublished - 1 Mar 2019

Fingerprint

Stomatitis
Hematopoietic Stem Cells
Transplants
Pain
Busulfan
Mucositis
Body Surface Area
Standard of Care
Observational Studies
Length of Stay
Body Mass Index
Body Weight
Prospective Studies
Surveys and Questionnaires

Keywords

  • Mucositis
  • OMDQ
  • Pain
  • Stem cell transplant
  • WHO oral toxicity scale

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

@article{bb9087c170014cfc8716cf9ba8831e05,
title = "A pilot study on effectiveness of oral mucositis pain control in hematopoietic stem cell transplant patients",
abstract = "Effectiveness of oral mucositis (OM) pain control with the current standard of care management was assessed using clinician and self-reported scales in hematopoietic stem cell transplant (HSCT) patients. A prospective observational study was performed using clinician-assessed [World Health Organization (WHO)] Oral Toxicity Scales and selfreported scales [Oral Mucositis Daily Questionnaires (OMDQ)]. A total of 23 HSCT patients were included in the study. There were 100 recorded days of OM using WHO scores, and 144 recorded days of OM using OMDQ. A total of 14/23 (60.9{\%}) patients experienced mucositis. The presence of OM was significantly associated with increase in actual body weight [t (21) = 2.15, p = 0.044], body surface area (BSA) [t (21) = 2.31, p = 0.031] and body mass index (BMI) [t(21) = 2.13, p = 0.044], longer hospital stays [t (21) = 2.45, p = 0.023], and busulphan-based regimens (χ = 4.32, p = 0.038). The degree of pain relief was significantly inversely correlated to both the degree of WHO graded OM severity (ρ = -0.586; p < 0.001) and the severity of self-reported pain (ρ = -0.375; p < 0.001). Both WHO and OMDQ significantly positively correlated in the clinical setting (p < 0.001). In conclusion, this study highlights the potential advantages of using patient self-reported scales in the local clinical setting. The use of the OMDQ self-reported scales could lead to earlier changes in therapy and may prove useful in HSCT patients.",
keywords = "Mucositis, OMDQ, Pain, Stem cell transplant, WHO oral toxicity scale",
author = "Wong, {Shu Ping} and Islahudin, {Farida Hanim}",
year = "2019",
month = "3",
day = "1",
doi = "10.7324/JAPS.2019.90305",
language = "English",
volume = "9",
pages = "27--32",
journal = "Journal of Applied Pharmaceutical Science",
issn = "2231-3354",
publisher = "MediPoeia",
number = "3",

}

TY - JOUR

T1 - A pilot study on effectiveness of oral mucositis pain control in hematopoietic stem cell transplant patients

AU - Wong, Shu Ping

AU - Islahudin, Farida Hanim

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Effectiveness of oral mucositis (OM) pain control with the current standard of care management was assessed using clinician and self-reported scales in hematopoietic stem cell transplant (HSCT) patients. A prospective observational study was performed using clinician-assessed [World Health Organization (WHO)] Oral Toxicity Scales and selfreported scales [Oral Mucositis Daily Questionnaires (OMDQ)]. A total of 23 HSCT patients were included in the study. There were 100 recorded days of OM using WHO scores, and 144 recorded days of OM using OMDQ. A total of 14/23 (60.9%) patients experienced mucositis. The presence of OM was significantly associated with increase in actual body weight [t (21) = 2.15, p = 0.044], body surface area (BSA) [t (21) = 2.31, p = 0.031] and body mass index (BMI) [t(21) = 2.13, p = 0.044], longer hospital stays [t (21) = 2.45, p = 0.023], and busulphan-based regimens (χ = 4.32, p = 0.038). The degree of pain relief was significantly inversely correlated to both the degree of WHO graded OM severity (ρ = -0.586; p < 0.001) and the severity of self-reported pain (ρ = -0.375; p < 0.001). Both WHO and OMDQ significantly positively correlated in the clinical setting (p < 0.001). In conclusion, this study highlights the potential advantages of using patient self-reported scales in the local clinical setting. The use of the OMDQ self-reported scales could lead to earlier changes in therapy and may prove useful in HSCT patients.

AB - Effectiveness of oral mucositis (OM) pain control with the current standard of care management was assessed using clinician and self-reported scales in hematopoietic stem cell transplant (HSCT) patients. A prospective observational study was performed using clinician-assessed [World Health Organization (WHO)] Oral Toxicity Scales and selfreported scales [Oral Mucositis Daily Questionnaires (OMDQ)]. A total of 23 HSCT patients were included in the study. There were 100 recorded days of OM using WHO scores, and 144 recorded days of OM using OMDQ. A total of 14/23 (60.9%) patients experienced mucositis. The presence of OM was significantly associated with increase in actual body weight [t (21) = 2.15, p = 0.044], body surface area (BSA) [t (21) = 2.31, p = 0.031] and body mass index (BMI) [t(21) = 2.13, p = 0.044], longer hospital stays [t (21) = 2.45, p = 0.023], and busulphan-based regimens (χ = 4.32, p = 0.038). The degree of pain relief was significantly inversely correlated to both the degree of WHO graded OM severity (ρ = -0.586; p < 0.001) and the severity of self-reported pain (ρ = -0.375; p < 0.001). Both WHO and OMDQ significantly positively correlated in the clinical setting (p < 0.001). In conclusion, this study highlights the potential advantages of using patient self-reported scales in the local clinical setting. The use of the OMDQ self-reported scales could lead to earlier changes in therapy and may prove useful in HSCT patients.

KW - Mucositis

KW - OMDQ

KW - Pain

KW - Stem cell transplant

KW - WHO oral toxicity scale

UR - http://www.scopus.com/inward/record.url?scp=85063739428&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063739428&partnerID=8YFLogxK

U2 - 10.7324/JAPS.2019.90305

DO - 10.7324/JAPS.2019.90305

M3 - Article

VL - 9

SP - 27

EP - 32

JO - Journal of Applied Pharmaceutical Science

JF - Journal of Applied Pharmaceutical Science

SN - 2231-3354

IS - 3

ER -